Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

57 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Pemetrexed combined with oxaliplatin or carboplatin as first-line treatment in advanced non-small cell lung cancer: a multicenter, randomized, phase II trial.
Scagliotti GV, Kortsik C, Dark GG, Price A, Manegold C, Rosell R, O'Brien M, Peterson PM, Castellano D, Selvaggi G, Novello S, Blatter J, Kayitalire L, Crino L, Paz-Ares L. Scagliotti GV, et al. Among authors: kortsik c. Clin Cancer Res. 2005 Jan 15;11(2 Pt 1):690-6. Clin Cancer Res. 2005. PMID: 15701857 Clinical Trial.
Randomized phase III study of gemcitabine and vinorelbine versus gemcitabine, vinorelbine, and cisplatin in the treatment of advanced non-small-cell lung cancer: from the German and Swiss Lung Cancer Study Group.
Laack E, Dickgreber N, Müller T, Knuth A, Benk J, Lorenz C, Gieseler F, Dürk H, Engel-Riedel W, Dalhoff K, Kortsik C, Graeven U, Burk M, Dierlamm T, Welte T, Burkholder I, Edler L, Hossfeld DK; German and Swiss Lung Cancer Study Group. Laack E, et al. Among authors: kortsik c. J Clin Oncol. 2004 Jun 15;22(12):2348-56. doi: 10.1200/JCO.2004.10.576. J Clin Oncol. 2004. PMID: 15197195 Clinical Trial.
Second-line (post-study) chemotherapy received by patients treated in the phase III trial of pemetrexed plus cisplatin versus cisplatin alone in malignant pleural mesothelioma.
Manegold C, Symanowski J, Gatzemeier U, Reck M, von Pawel J, Kortsik C, Nackaerts K, Lianes P, Vogelzang NJ. Manegold C, et al. Among authors: kortsik c. Ann Oncol. 2005 Jun;16(6):923-7. doi: 10.1093/annonc/mdi187. Epub 2005 Apr 11. Ann Oncol. 2005. PMID: 15824080 Free article. Clinical Trial.
The efficacy and safety of BI 2536, a novel Plk-1 inhibitor, in patients with stage IIIB/IV non-small cell lung cancer who had relapsed after, or failed, chemotherapy: results from an open-label, randomized phase II clinical trial.
Sebastian M, Reck M, Waller CF, Kortsik C, Frickhofen N, Schuler M, Fritsch H, Gaschler-Markefski B, Hanft G, Munzert G, von Pawel J. Sebastian M, et al. Among authors: kortsik c. J Thorac Oncol. 2010 Jul;5(7):1060-7. doi: 10.1097/JTO.0b013e3181d95dd4. J Thorac Oncol. 2010. PMID: 20526206 Free article. Clinical Trial.
Molecular biomarkers in non-small-cell lung cancer: a retrospective analysis of data from the phase 3 FLEX study.
O'Byrne KJ, Gatzemeier U, Bondarenko I, Barrios C, Eschbach C, Martens UM, Hotko Y, Kortsik C, Paz-Ares L, Pereira JR, von Pawel J, Ramlau R, Roh JK, Yu CT, Stroh C, Celik I, Schueler A, Pirker R. O'Byrne KJ, et al. Among authors: kortsik c. Lancet Oncol. 2011 Aug;12(8):795-805. doi: 10.1016/S1470-2045(11)70189-9. Epub 2011 Jul 22. Lancet Oncol. 2011. PMID: 21782507
A phase II study of irinotecan (CPT-11) and carboplatin in patients with limited disease small cell lung cancer (SCLC).
Laack E, Thöm I, Krüll A, Engel-Riedel W, Müller T, Meissner C, Dürk H, Fischer J, Gütz S, Kortsik C, Elbers M, Schuch G, Andritzky B, Görn M, Burkholder I, Edler L, Hossfeld DK, Bokemeyer C. Laack E, et al. Among authors: kortsik c. Lung Cancer. 2007 Aug;57(2):181-6. doi: 10.1016/j.lungcan.2007.03.001. Epub 2007 Apr 17. Lung Cancer. 2007. PMID: 17442447 Clinical Trial.
Open, randomized, multi-center phase II study comparing efficacy and tolerability of Erlotinib vs. Carboplatin/Vinorelbin in elderly patients (>70 years of age) with untreated non-small cell lung cancer.
Heigener DF, Deppermann KM, Pawel JV, Fischer JR, Kortsik C, Bohnet S, Eiff MV, Koester W, Thomas M, Schnabel PA, Reck M. Heigener DF, et al. Among authors: kortsik c. Lung Cancer. 2014 Apr;84(1):62-6. doi: 10.1016/j.lungcan.2014.01.024. Epub 2014 Feb 3. Lung Cancer. 2014. PMID: 24560332 Clinical Trial.
The gefitinib long-term responder (LTR)--a cancer stem-like cell story? Insights from molecular analyses of German long-term responders treated in the IRESSA expanded access program (EAP).
Gottschling S, Herpel E, Eberhardt WE, Heigener DF, Fischer JR, Köhne CH, Kortsik C, Kuhnt T, Muley T, Meister M, Bischoff HG, Klein P, Moldenhauer I, Schnabel PA, Thomas M, Penzel R. Gottschling S, et al. Among authors: kortsik c. Lung Cancer. 2012 Jul;77(1):183-91. doi: 10.1016/j.lungcan.2012.03.003. Epub 2012 Apr 7. Lung Cancer. 2012. PMID: 22483783
57 results